Navigation Links
Osteotech's Plexur P(TM) Receives FDA Clearance as Bone Void Filler and Bone Graft Extender in Spine
Date:4/25/2008

EATONTOWN, N.J., April 25 /PRNewswire-FirstCall/ -- Osteotech, Inc. (Nasdaq: OSTE), a leader in the emerging field of biologic solutions for regenerative medicine, announced today that the United States Food and Drug Administration ("FDA") has cleared its 510(k) submission for the Plexur P(TM) Biocomposite for use in spinal applications as a bone void filler and as a bone graft extender. Previously, Osteotech received FDA clearance for Plexur P(TM) for use in filling bony voids of the pelvis and extremities.

Sam Owusu-Akyaw, Osteotech's President and Chief Executive Officer, stated, "We are very pleased to receive FDA clearance for the use of our Plexur P(TM) product in the spine. We continue to receive many favorable comments from orthopedic surgeons about the efficacy of Plexur P(TM) and we will immediately offer our Plexur P(TM) product to spine surgeons supported by the clinical information and experience we have gained over the last year. Our proprietary Plexur(R) Technology continues to be one of the keys to our product pipeline and future growth initiatives."

To date, the Plexur P(TM) Biocomposite has been used by a variety of surgeons in tibial plateau fractures, tibial osteotomies and a variety of foot and ankle procedures, and can now be used in the spine. Our Plexur P(TM) product can be combined with our proprietary Grafton(R) DBM, local bone or our new Kinesis(TM) BMAC(TM) cellular system. Plexur P(TM) is available as granules, cylinders, blocks, wedges and sheets. For more information about the Plexur P(TM) Biocomposite, please go to our websites at http://www.plexur.com or http://www.osteotech.com.

The
'/>"/>

SOURCE Osteotech, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Osteotech Receives FDA Clearance for Plexur M(TM) Biocomposite
2. Diamics Receives European CE Mark Approval for Its Pap-Map(TM) System for Cervical Cancer Screening
3. Angiotech elects to suspend Vascular Wrap(TM) pivotal clinical trials
4. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
5. Ciphergen Biosystems Receives Noncompliance Letter From The Nasdaq Stock Market
6. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
7. Anesiva Receives FDA Approval for Zingo(TM), a New, Innovative Product to Reduce Pain Associated with Needle Insertion Procedures in Children
8. IsoTis Receives FDA Clearance for Accell Family of Products
9. Actavis Receives Approval of Fentanyl Transdermal System in the U.S.
10. AGA Medical Corporation Receives FDA and CE Mark Approvals for the AMPLATZER Vascular Plug II
11. IDM Pharma Receives Not Approvable Letter for Mifamurtide (L-MTP-PE) for the Treatment of Osteosarcoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... Research and Markets ... of the "Oxidative Stress Assay Market ... (Indirect, Enzyme-based, Reactive Oxygen Species (ROS)-based), Technology ... Global Forecast to 2020" report to ... , The global oxidative stress ...
(Date:6/1/2015)... 1, 2015 GenomeDx Biosciences today ... platform, successfully classified various subtypes of bladder ... certain biomarkers, including one type associated with ... genomic signature has potential as a tool ... in patients with muscle-invasive bladder cancers (MIBC). ...
(Date:6/1/2015)... June 1, 2015  Novartis is highlighting data ... CTL019, an investigational chimeric antigen receptor (CAR) T ... treatment of specific types of hard-to-treat non-Hodgkin lymphoma. ... University of Pennsylvania,s Perelman School of Medicine (Penn) ... large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) ...
(Date:6/1/2015)... Regis Technologies, Inc. is a ... stationary phases (CSPs) for analytical and preparative chromatography ... presenting solutions for new clients, Regis implemented a ... addition to its core expertise in chiral chromatography ... tackle projects for the scale clients need–from milligram ...
Breaking Biology Technology:Oxidative Stress Assay Market 2015 - Global Forecast to 2020 2GenomeDx's Decipher Platform Validates Genomic Signature that may Predict Resistance to Chemotherapy in Bladder Cancer Patients in Study Presented at ASCO 2015 Annual Meeting 2GenomeDx's Decipher Platform Validates Genomic Signature that may Predict Resistance to Chemotherapy in Bladder Cancer Patients in Study Presented at ASCO 2015 Annual Meeting 3GenomeDx's Decipher Platform Validates Genomic Signature that may Predict Resistance to Chemotherapy in Bladder Cancer Patients in Study Presented at ASCO 2015 Annual Meeting 4Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 2Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 3Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 4Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 5Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 6Regis Technologies Offers Chiral Chromatography Service 2Regis Technologies Offers Chiral Chromatography Service 3
... NEW YORK, Nov. 29, 2011  Roche (SIX: RO, ROG; OTCQX: ... announced today a licensing agreement for PTC,s Spinal Muscular ... that causes muscle weakness. One in every 10,000 children ... no effective treatment. PTC Therapeutics, programme ...
... CHICAGO, Nov. 29, 2011 Sundberg , a leading ... appliance and HVAC parts, is kicking ... the opening of a new headquarters facility and two state-of-the-art ... in the development of two world-class, logistically centric warehouses: a ...
...   Bacterin International Holdings, Inc. (NYSE Amex: ... revolutionary bone graft material and antimicrobial coatings for medical ... for distribution in the U.S. and Canada of Jeil,s ... of orthopedic implants used in craniomaxillofacial procedures, including trauma ...
Cached Biology Technology:Roche Signs Agreement with PTC Therapeutics to Advance Treatment for Spinal Muscular Atrophy (SMA) 2Roche Signs Agreement with PTC Therapeutics to Advance Treatment for Spinal Muscular Atrophy (SMA) 3Roche Signs Agreement with PTC Therapeutics to Advance Treatment for Spinal Muscular Atrophy (SMA) 4Sundberg Kicks Off National Expansion With Openings of New Headquarters, Logistically Centric Mega Warehouses 2Bacterin Signs Distribution Agreement with Jeil for 'LeForte Craniomaxillofacial System' 2Bacterin Signs Distribution Agreement with Jeil for 'LeForte Craniomaxillofacial System' 3Bacterin Signs Distribution Agreement with Jeil for 'LeForte Craniomaxillofacial System' 4
(Date:5/11/2015)... JOSE, Calif. , May 11, 2015 /PRNewswire/ ... developer of human interface solutions, today announced the ... Vice President and Chief Financial Officer, reporting to ... Ali replaces Synaptics, current Chief Financial Officer, ... December 2014. Mr. Ali brings ...
(Date:5/10/2015)... , May 11, 2015 Fingerprint Cards ... FPC1025 and FPC1155 from the distributor World Peace Industrial Group ... distributors in Asia . Deliveries are planned ... be used by smartphone manufacturers in China ... the communicated revenue guidance of + 1 000 MSEK for 2015. ...
(Date:5/6/2015)... TEL AVIV, Israel , May 6, 2015 /PRNewswire/ ... the world,s most established helmet producer, announced today that ... LifeBEAM Smart Helmet, the world,s first bio-sensing cycling helmet ... will be released in two new colors in order ... demand for the product. In addition, LifeBEAM and Lazer ...
Breaking Biology News(10 mins):Synaptics Appoints Wajid Ali as Senior Vice President and Chief Financial Officer 2Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 235 Million 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 3
... University of Chicago show how the bacteria that cause the ... slightly altering one of the microbe's tools, the researchers produced ... Both papers -- one published online July 28 in Science ... Immunity -- focus on aspects of the type-III pathway, a ...
... understanding of exactly how the brain controls breathing is ... that breathing is an automatic rhythmic process that persists ... but the question that has intrigued many scientists for ... fail safe vital rhythm throughout life? , Experimental Physiology ...
... Services University of the Health Sciences (USU), the ... Cancer Institute (NCI) have made a major breakthrough ... could be engineered for use as bioweapons. The ... and Hendra viruses--naturally occurring and highly pathogenic paramyxoviruses ...
Cached Biology News:Studies reveal how plague disables immune system, and how to exploit the process to make a vaccine 2Studies reveal how plague disables immune system, and how to exploit the process to make a vaccine 3Studies reveal how plague disables immune system, and how to exploit the process to make a vaccine 4How exactly does the brain control breathing? 2Discovery could be key to bioterrorism defense 2Discovery could be key to bioterrorism defense 3
...
... cDNA normalization is essential for hunting ... high-throughput approaches, such as EST sequencing ... Evrogen TRIMMER-DIRECT kit is developed for ... sequences and intended for directional cloning. ...
Peptide-affinity Purified Polyclonal Antibody to ICEBERG Peptide with sequence EEDPQLASKMGLH, from C Terminus of the protein sequence according to NP_067546...
Purified anti-Fanconi anemia D2-Phosphorylated (Ser222)...
Biology Products: